Review of 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Post-publication Review of

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Reviewed On August 15, 2017

Reviewed by

Actions

Content of review 1, reviewed on August 15, 2017

I reviewed this

Source

References

Florent, B., Markus, J., Martin, F., Dirk, K., Francesco, Z., Martin, B. 2017. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. Journal of Translational Medicine.